Valuation implications of pharmaceutical companies' R&D regulatory approval notifications

This paper examines shareholder wealth effects surrounding applications to, and approvals by, the United States Food and Drug Administration (FDA) for firms listed on the New York (NYSE) and London (LSE) stock exchanges. Applications to the FDA for drug approvals significantly increase shareholder w...

Full description

Saved in:
Bibliographic details
Volume: 45
Main Author: Hamill, Philip A
McIlkenny, Philip
Opong, Kwaku K
Format: Journal Article
Language: English
Zielgruppe: Academic
Place of publication: OXFORD Elsevier Ltd 01.06.2013
Elsevier B.V
published in: The British accounting review Vol. 45; no. 2; pp. 99 - 111
ORCID: 0000-0002-2390-1667
Data of publication: June 2013
ISSN: 0890-8389
EISSN: 1095-8347
Discipline: Business
Online Access: available in Bonn?
Database: Web of Knowledge
Social Sciences Citation Index
Web of Science
Web of Science - Social Sciences Citation Index - 2013
Academic OneFile (A&I only)
Database information Databases - DBIS